2026-08-10T01:44:25Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/264172025-12-18T13:01:21Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968

00925njm 22002777a 4500 dc Merdrignac, Lore author Laniece Delaunay, Charlotte author Verdasca, Nuno author Vega-Piris, Lorena author O'Donnell, Joan author Sève, Noémie author Trobajo-Sanmartín, Camino author Buda, Silke author Hooiveld, Mariëtte author Rodrigues, Ana Paula author Túri, Gergő author Latorre-Margalef, Neus author Mlinarić, Ivan author Lazar, Mihaela author Maurel, Marine author Castrillejo, Daniel author Bennett, Charlene author Rameix-Welti, Marie-Anne author Martínez-Baz, Iván author Dürrwald, Ralf author Meijer, Adam author Melo, Aryse author Oroszi, Beatrix author Hagey, Tove Samuelsson author Kurečić Filipović, Sanja author Dijkstra, Frederika author Gomez, Verónica author Bacci, Sabrina author Kaczmarek, Marlena author Kissling, Esther author VEBIS Primary Care Vaccine Effectiveness Group author 2024-11 We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12-71), 23% (95% CI: -11-48) and 5% (95% CI: -92-56) among those with symptom onset 1-5, 6-11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection. Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O'Donnell J, Sève N, Trobajo-Sanmartín C, Buda S, Hooiveld M, Rodrigues AP, Túri G, Latorre-Margalef N, Mlinarić I, Lazar M, Maurel M, Castrillejo D, Bennett C, Rameix-Welti MA, Martínez-Baz I, Dürrwald R, Meijer A, Melo A, Oroszi B, Hagey TS, Kurečić Filipović S, Dijkstra F, Gomez V, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024. Influenza Other Respir Viruses. 2024 Nov;18(11):e70009. 10.1111/irv.70009 1750-2659 1750-2640 Influenza and other respiratory viruses 39523781 https://hdl.handle.net/20.500.12105/26417 COVID‐19 SARS‐CoV‐2 Case–control study Multi‐country study Primary care Test‐negative design Vaccine effectiveness Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024